<DOC>
	<DOCNO>NCT00862420</DOCNO>
	<brief_summary>Primary objective : - To evaluate whether 12 week clopidogrel superior ticlopidine term low risk safety event interest patient peripheral arterial disease ( PAD ) Secondary objective : - To compare risk bleed adverse event , serious adverse event overall safety clopidogrel ticlopidine - To compare risk vascular event clopidogrel ticlopidine - To document long-term safety clopidogrel total 52 week - To document vascular event clopidogrel total 52 week</brief_summary>
	<brief_title>Safety Evaluation Clopidogrel Sulfate Patients With Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Documented symptomatic peripheral arterial disease ( one follow two primary criterion must satisfy ) : Current intermittent claudication Ankle Brachial Index ( ABI ) &lt; 0.90 A history intermittent claudication together previous relate intervention leg Patients acute atherothrombotic event invasive therapy within 30 day randomization , patient plan invasive therapy within 12 week randomization Bleeding diathesis , coagulopathy present bleed disease Previous intracranial bleeding hemorrhagic stroke Uncontrolled hypertension The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Platelet aggregation inhibitor</keyword>
	<keyword>Peripheral arterial disease ( PAD )</keyword>
</DOC>